Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases

Autor:	Nádia Emi Aikawa, Leonard de Vinci Kanda Kupa, Ana Cristina Medeiros-Ribeiro, Carla Goncalves Schahin Saad, Emily Figueiredo Neves Yuki, Sandra Gofinet Pasoto, Priscila Tagliaferro Rojo, Rosa Maria Rodrigues Pereira, Samuel Katsuyuki Shinjo, Percival Degrava Sampaio-Barros, Danieli Castro Oliveira Andrade, Ari Stiel Radu Halpern, Ricardo Fuller, Fernando Henrique Carlos Souza, Lissiane Karine Noronha Guedes, Ana Paula Luppino Assad, Julio Cesar Bertacini de Moraes, Michelle Remiao Ugolini Lopes, Victor Adriano de Oliveira Martins, Lorena Betancourt, Carolina Torres Ribeiro, Lucas Peixoto Sales, Isabela Maria Bertoglio, Virginia Lucia Nazario Bonoldi, Renata Lys Pinheiro Mello, Gustavo Guimaraes Moreira Balbi, Ana Marli Christovam Sartori, Leila Antonangelo, Clóvis Artur Silva, Eloisa Bonfa
Rok vydání:	2022
Předmět:	Adult Male COVID-19 Vaccines SARS-CoV-2 Immunology COVID-19 Antibodies Viral General Biochemistry Genetics and Molecular Biology Autoimmune Diseases Immunogenicity Vaccine Rheumatology Immunoglobulin G Rheumatic Diseases Humans Prednisone Immunology and Allergy Female
Zdroj:	Annals of the Rheumatic Diseases. 81:1036-1043
ISSN:	1468-2060 0003-4967
DOI:	10.1136/annrheumdis-2021-222096
Popis:	ObjectiveTo determine the immunogenicity of the third dose of CoronaVac vaccine in a large population of patients with autoimmune rheumatic diseases (ARD) and the factors associated with impaired response.MethodsAdult patients with ARD and age-balanced/sex-balanced controls (control group, CG) previously vaccinated with two doses of CoronaVac received the third dose at D210 (6 months after the second dose). The presence of anti-SARS-CoV-2 S1/S2 IgG and neutralising antibodies (NAb) was evaluated previously to vaccination (D210) and 30 days later (D240). Patients with controlled disease suspended mycophenolate mofetil (MMF) for 7 days or methotrexate (MTX) for 2 weekly doses after vaccination.ResultsARD (n=597) and CG (n=199) had comparable age (p=0.943). Anti-S1/S2 IgG seropositivity rates significantly increased from D210 (60%) to D240 (93%) (pConclusionsWe provide novel data on a robust response to the third dose of CoronaVac in patients with ARD, even in those with prevaccination COVID-19 seronegative status. Drugs implicated in reducing immunogenicity after the regular two-dose regimen were associated with non-responsiveness after the third dose, except for MTX.Trial registration numberNCT04754698.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43f5681a338b00b8a20fd8f4a8bdb9bf https://doi.org/10.1136/annrheumdis-2021-222096 Zobrazit plný text záznamu